Beijing Hotgen Biotech Co., Ltd. (referred to as "Hotgen Biotech"), founded in 2005, is a high-tech enterprise focusing on the biomedical field. It was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in September 2019 (stock code: 688068).
The company has been continuously exploring independent innovative diagnostic technology platforms and has established multi-omics diagnostic technology platforms including protein markers, glycan exosomes, and DNA methylation. Its innovative technology incubation platform, the Future Technology Research Institute, focuses on exploring the transformation of cutting-edge technologies and has now laid out frontier fields such as nucleic acid drugs, antibody drugs, and biotechnology consumer products. The world's first emergency antibody drug for myocardial infarction has obtained dual IND approvals in China and the United States, as well as FDA Fast Track designation. Adhering to the mission of "Developing biotechnology for the benefit of human health", the company is committed to building an integrated industrial chain development strategy from characteristic diagnostics to innovative pharmaceuticals.
